Get the Stockscreener App
63.53
1.11%
0.695
After Hours:
63.54
0.005
+0.01%
Kiniksa Pharmaceuticals International Plc stock is traded at $63.53, with a volume of 834.31K.
It is up +1.11% in the last 24 hours and up +7.32% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
See More
Previous Close:
$62.84
Open:
$62.96
24h Volume:
834.31K
Relative Volume:
1.10
Market Cap:
$4.89B
Revenue:
$754.05M
Net Income/Loss:
$73.06M
P/E Ratio:
70.03
EPS:
0.9073
Net Cash Flow:
$164.23M
1W Performance:
+1.53%
1M Performance:
+7.32%
6M Performance:
+42.33%
1Y Performance:
+141.30%
1-Day Range:
$62.79
$64.85
1-Week Range:
$61.60
$64.85
52-Week Range:
$26.51
$67.53
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
63.53 | 4.83B | 754.05M | 73.06M | 164.23M | 0.9073 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Canaccord Genuity | Buy |
| Sep-29-25 | Initiated | TD Cowen | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Kiniksa Pharmaceuticals International PLC (KNSA) Cash Flow - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2026: Everyt - GuruFocus
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High-Growth Stock with Strong Technical Setup - ChartMill
KNSA|Kiniksa Pharmaceuticals International PLC|Price:62.840|Chg%:-0.210 - TradingKey
Kiniksa Pharmaceuticals International PLC - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
Granahan Investment Management LLC Cuts Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Spruce Street Capital LP Has $36.65 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc Revenue Breakdown – NASDAQ:KNSA - TradingView
Zacks.com featured highlights include American Outdoor Brands, Cimpress, National Energy Services Reunited, CTO Realty Growth and Kiniksa Pharmaceuticals International - The Globe and Mail
Kiniksa Pharmaceuticals International, PLC expected to post earnings of 30 cents a shareEarnings Preview - TradingView
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High Growth Momentum Stock With a Breakout Setup - ChartMill
Kiniksa Pharmaceuticals to report Q2 2026 results in conference call and webcast - Bitget
Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026 - The Manila Times
Kiniksa to discuss portfolio execution in July 28 webcast - Stock Titan
KNSA Maintained by Goldman Sachs -- Price Target Raised to $75 - GuruFocus
5 Stocks With Recent Price Strength Despite Recent Market Volatility - TradingView
Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why - Yahoo Finance
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Qualifies as an Affordable Growth Stock With Strong Revenue and Earnings Momentum - ChartMill
Kiniksa Pharmaceuticals International, plc (KNSA) is a great choice for 'trend' investors, here's why - MSN
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 4. - GuruFocus
Dhiraj H Malkani Net Worth (2026) - GuruFocus
Price to sales forward of Kiniksa Pharmaceuticals International, plc – NASDAQ:KNSA - TradingView
Price to book forward of Kiniksa Pharmaceuticals International, plc – NASDAQ:KNSA - TradingView
Kiniksa Pharmaceuticals Leads Small-Cap Stocks with 119.62% Return - MarketsMojo
Kiniksa Pharmaceuticals: Leader In Pericarditis Merits Hold Rating After Recent Gains - Seeking Alpha
KNSA Maintained by Wells Fargo -- Price Target Raised to $74.00 - GuruFocus
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Kiniksa Pharmaceuticals International, plc (KNSA) surges 5.4%: Is this an indication of further gains? - MSN
Kiniksa Pharmaceuticals International (KNSA) Joins Russell Indexes, Is The Upside Already Priced In? - Yahoo Finance
Illumina, Inc. (ILMN) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 7. - GuruFocus
Will Broad Russell Index Inclusion Reshape Kiniksa Pharmaceuticals' (KNSA) ARCALYST-Centered Growth Narrative? - simplywall.st
Performance share awards at Kiniksa (NASDAQ: KNSA) tied to KPL-387 FDA goals - Stock Titan
Kiniksa (KNSA) Chief Strategy Officer named as insider in Form 3 - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Kiniksa Pharmaceuticals Q1 2026 Earnings: Strong EPS Beat Drives Stock HigherTrough Earnings Signal - DonanımHaber
Here's why you should add Kiniksa stock to your portfolio now - MSN
What makes Kiniksa Pharmaceuticals International, plc (KNSA) a strong momentum stock: Buy now? - MSN
Kiniksa Pharmaceuticals Hits New 52-Week High of USD 59.89 - MarketsMojo
Kiniksa Pharmaceuticals Hits New 52-Week High of USD 63.77 - MarketsMojo
Peregrine Capital Management LLC Sells 29,550 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Inspire Investing LLC Makes New $1.70 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Pictet Asset Management Holding SA Sells 164,232 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains? - Yahoo Finance
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):